A Study To Evaluate The Safety Of CMTX-101 In People With Cystic Fibrosis

Cystic Fibrosis Clinical Trial

Official title:

A Phase 1b/2a Study To Evaluate The Safety Of CMTX-101 In Combination With Inhaled Tobramycin In People With Cystic Fibrosis Chronically Infected With Pseudomonas Aeruginosa

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06159725
• Other study ID #: CMTX101-P1-CT002
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: January 17, 2024
• Est. completion date: February 2025

Study information

• Verified date: February 2024
• Source: Clarametyx Biosciences, Inc.
• Contact: Teresa Byrne
• Phone: 4844677678
• Email: tbyrne[@]clarametyx.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

CMTX-101 is a bacterial biofilm disrupting monoclonal antibody being developed as an adjunctive therapy to standard of care antibiotics. The goal of this clinical trial is to assess the safety and tolerability of CMTX-101 in people with cystic fibrosis (pwCF).

The main questions the study aims to answer are:

• Are single doses of CMTX-101 IV infusion safe and tolerated

• What is the pharmacokinetic (PK) profile of single doses of CMTX-101

• Do single doses of CMTX-101 induce development of anti-drug antibodies (ADA) and neutralizing antibodies (Nabs)

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 41
• Est. completion date: February 2025
• Est. primary completion date: February 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Adults =18 years of age at the time of screening.

2. Confirmed CF diagnosis based on current CF Foundation (CFF)-sponsored guidelines.

3. For participants on modulator therapy, they must be on a stable dose of TRIKAFTA (ETI) modulator therapy for at least 3 months.

4. Willing and capable of providing induced sputum for evaluation at defined study timepoints.

5. Positive P. aeruginosa growth of =104 CFU/gram from a sample of induced sputum at the screening visit.

6. FEV1 =50% (Part1) or =35% (Part 2) of predicted normal value at screening.

7. Currently receiving inhaled tobramycin alone or CAT therapy. At least one 28-day cycle completed within 8 weeks prior to screening visit.

• Note: If on CAT therapy, initiation of inhaled tobramycin should begin approximately 2 hours (±1 hour) pre-dose.

8. Women of childbearing potential (WOCBP) must have a negative serum beta-human chorionic gonadotropin test during screening and agree to use an effective method of contraception for the duration of the study and for 4 months after the last infusion of study drug. A female participant is considered of childbearing potential unless postmenopausal or surgically sterilized and at least 3 months has passed since sterilization procedure. Female surgical sterilization procedures include tubal ligation, bilateral salpingectomy, hysterectomy, or bilateral oophorectomy. A female participant is considered postmenopausal if she has had spontaneous amenorrhea for at least 2 years with an appropriate clinical profile (e.g., age appropriate, history of vasomotor symptoms).

• Effective methods of contraception include (a) abstinence, (b) partner vasectomy, (c) intrauterine devices, (d) hormonal implants (such as Implanon), or (e) other hormonal methods (birth control pills, injections, patches, vaginal rings).

9. Male participants with a female partner must use a medically accepted contraceptive regimen during his participation in the study and for 4 months after study drug infusion.

• Acceptable methods of contraception for male participants include condoms with spermicide, surgical sterilization of the participant (i.e., vasectomy) at least 26 weeks before screening, or sexual abstinence (i.e., refraining from heterosexual intercourse) if that is the preferred and usual lifestyle of the participant.

10. Male participants must agree to abstain from sperm donation through 4 months after study drug administration.

11. Capable of providing informed consent.

12. Capable and willing to complete all study visits and perform all procedures required by the protocol.

Exclusion Criteria:

1. Body mass index (BMI) <14 at screening and baseline.

2. Has a known history or evidence of human immunodeficiency virus (HIV) infection or chronic hepatitis B screening.

3. Tests positive for hepatitis C virus (HCV) RNA at screening.

4. Changes in underlying therapy (e.g., pulmonary massage therapy, bronchodilators, nonsteroidal anti-inflammatory drugs [NSAIDs], antibiotic agents, pancreatic enzyme preparations, nutritional supplements, and DNase) within the 21 days before, and inclusive of, study baseline or anticipated changes to underlying therapy during the study.

5. Pulmonary exacerbation within 28 days of baseline.

6. Requirement for continuous (24 hour/day) oxygen supplementation; periodic use is permitted.

7. Participation in smoking or vaping activity in the last 6 months.

8. History of, or planned, organ transplantation.

9. Elevated liver function tests obtained at screening.

1. ALT >5 × ULN or AST >5 × ULN, or

2. Total bilirubin >3 × ULN or Total bilirubin >1.5 × ULN combined with either ALT >3 × ULN or AST >3 × ULN. ULN reflects local laboratory ranges.

10. Greater than 5 ml of hemoptysis on one occasion or >30 mL of hemoptysis in a 24-hour period within 28 days of baseline.

11. Infection with other more pathogenic organisms such as Mycobacterium abscessus or Burkholderia spp., where the investigator feels that the participant either is not or will not remain clinically stable throughout the duration of the study.

12. Acute clinical illness requiring a new (oral, parenteral, or inhaled) antibiotic(s) =30 days prior to the baseline visit. Does not include chronic suppressive medications or cyclic dosing medications such as inhaled antibiotics.

13. Women who are pregnant, planning to become pregnant during the study period or for 4 months following last infusion of study drug, or breastfeeding.

14. Active treatment of any mycobacterial or fungal organisms =30 days prior to baseline visit. Chronic treatment for suppression of fungal populations is allowable.

15. Anticipated need to change chronic (either inhaled or oral) antibiotic regimens during the study period. Participants must agree to maintain their current chronic antibiotic regimen from the screening visit for the duration of the follow-up period (approximately 30 days).

16. Known allergy to any component of the study drug.

17. Participant with an estimated glomerular filtration rate <60 mL/min/1.73 m2.

18. Any significant finding that, in the opinion of the investigator, would make it unsafe for the participant to participate in this study or would not be in the best interest of the participant.

19. Enrolled in an interventional clinical study within =60 days of the baseline visit, or participating in a clinical study while enrolled in this clinical study (inclusive of vaccine studies).

20. Currently or previously enrolled in this study.

Related Conditions & MeSH terms

• Cystic Fibrosis
• Fibrosis
• Persistent Infection

Intervention

Drug:
• CMTX-101
CMTX-101 is a humanized monoclonal antibody administered as a single IV infusion over approximately 60 minutes.
• Placebo
Placebo is normal saline administered as a single IV infusion over approximately 60 minutes.

Locations

Country	Name	City	State
United States	University of Michigan	Ann Arbor	Michigan
United States	St Luke's Sleep Medicine and Research Center	Boise	Idaho
United States	Boston Children's Hospital	Boston	Massachusetts
United States	Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center	Cleveland	Ohio
United States	Nationwide Children's Hospital	Columbus	Ohio
United States	National Jewish Health	Denver	Colorado
United States	New York Medical College	Hawthorne	New York
United States	PennState Health	Hershey	Pennsylvania
United States	Central Florida Pulmonary Group, PA	Orlando	Florida
United States	Stanford University	Palo Alto	California
United States	University of Utah	Salt Lake City	Utah
United States	Seattle Children's Hospital	Seattle	Washington

Sponsors (1)

Lead Sponsor	Collaborator
Clarametyx Biosciences, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number and % of participants experiencing adverse events following a single IV infusion of CMTX-101	Primary objective	Day 1 to Day 28
Primary	Number and % of participants experiencing serious adverse events following a single IV infusion of CMTX-101	Primary objective	Day 1 to Day 28
Secondary	Assess the CMax - observed maximum plasma concentration determined by ELISA following a single IV infustion of CMTX-101	Secondary objective	Day 1 to Day 35
Secondary	Assess the TMax - time to reach maximum concentration curve following a single IV infusion of CMTX-101	Secondary objective	Day 1 to Day 35
Secondary	Assess the AUC0-8 Area under the concentration time curve from zero to infinite time following a single IV infusion of CMTX-101	Secondary objective	Day 1 to Day 35
Secondary	Assess the Terminal phase elimination rate determined by ELISA following a single IV infusion of CMTX-101	Secondary objective	Day 1 to Day 35
Secondary	Assess the Terminal elimination half- determined by ELISA following a single IV infusion of CMTX-101	Secondary objective	Day 1 to Day 35
Secondary	Assess the Apparent total body clearance (CL/F) determined by ELISA following a single IV infusion of CMTX-101	Secondary objective	Day 1 to Day 35
Secondary	Assess the Apparent volume distribution (Vx/F) determined by ELISA following a single IV infustion of CMTX-101	Secondary objective	Day 1 to Day 35
Secondary	Evaluate the immunogenicity of CMTX-101 as measured by anti-drug antibodies (ADA) determined by the electrochemiluminescence assay following a single IV infustion of CMTX-101	Secondary objective	Day 1 to Day 35
Secondary	Assess the apparent reduction in pulmonary P. auriginosa burden as measured by quantitative microbial culture of sputum	Secondary objective	Day 1 to Day 28